Back to Top


BLU Ampersand, Inc.

Since the introduction of targeted therapeutics in the late 1990s, the drug development pipeline has expanded to include thousands of small molecules and biologics. More than a thousand oncology agents are evaluated in >40,000 clinical trials, to add to the millions of publications already available.

Dynamic changes in the clinical and competitive landscape provide a significant challenge to successfull drug development and optimal patient care. BLU Ampersand creates the tools that bring current and relevant information together in one place – so you can plan for success.

Our company merges scientific expertise, innovative information technology, and strategic thinking; this unique blend of skills is well represented by the & (am-per-sand: noun, 1. a character or symbol for and).